LD-2 disclosure · 2nd Quarter - Report
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA
Client
- Description
- Represents the leading research-based pharmaceutical companies in the US.
- Location
- District of Columbia · United States of America
Registrant
- Description
- Consulting
- Location
- Washington, District of Columbia, United States of America
Lobbying activities
3 issuesMedicare/Medicaid
Access and reimbursement in Medicare Parts B and D. Implementation of provisions included in Subtitle B of PL.117-169- Inflation Reduction Act of 2022. Support for EPIC Act - S. 832, and H.R. 1492, To equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act Policies related to the Most Favored Nation Drug Pricing Model
LobbyistsJOHN MCMANUS · ALEX WHALEN
TargetedSENATE · HOUSE OF REPRESENTATIVES
Health Issues
Issues related to reforming and increasing transparency within the 340B Drug Pricing Program.
LobbyistsJOHN MCMANUS · ALEX WHALEN
Covered position (JOHN MCMANUS): Staff Director W&M Health Subcommittee; LA, Rep. Bill Thomas
TargetedSENATE · HOUSE OF REPRESENTATIVES
Taxation/Internal Revenue Code
Issues related to the Tax Exempt Hospital Transparency Act (H.R. 9504).
LobbyistsJOHN MCMANUS · ALEX WHALEN